This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
IN THE late 1970s, Thomas Merigan, MD, and colleagues at Stanford (Calif) University School of Medicine noticed that patients with chronic active hepatitis B who had been receiving prednisone responded to interferon treatment better than patients who had not received steroids.
At that time, corticosteroid treatment for chronic hepatitis B was losing favor, and a way to manufacture commercial amounts of interferon had just been discovered. Merigan, who now heads Stanford's Division of Infectious Diseases, and his group first described the steroid-antiviral connection in an article six years ago (J Infect Dis 1981;143:772-783). But, enthusiasm for interferon, and later for the other new antiviral substances, was high. So, the investigators continued studying these as single-drug therapy.
Today, the high hope many hepatitis researchers had for interferon and other antivirals is waning. These days, "everybody [in hepatitis B research] is doing combined-therapy trials," says Myron Tong, MD, PhD, professor of medicine,
Kirn TF. Corticosteroid-Interferon Therapy for Hepatitis B Characterized as 'Potentially Exciting' so Far. JAMA. 1987;258(4):427–432. doi:10.1001/jama.1987.03400040017004